Silibinin

Phase 2Small molecule

RRottapharm

Silibinin is one of 68 small molecule programs targeting Hepatic failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic FailureActive, not recruiting

Liver TransplantActive, not recruiting

Hepatic FailurePhase 2

Active, not recruiting

Liver TransplantPhase 2

Active, not recruiting

Competition

Competitive Landscape

353 competitors in Liver Transplant

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Preclinical

3 2

Vemlidy

Gilead

Preclinical

3 3

Lenvima

Eisai

Preclinical

2 4

Octreotide

Johnson & Johnson

Preclinical

2 5

Beyfortus

BeiGene

Preclinical

1 6

Prostigmin

Merck & Co.

Preclinical

1 7

Myfortic

Novartis

Preclinical

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 9

Silibinin

RRottapharm

Phase 2

2 10

Myfortic

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Trial2 trials

Trial of Indole-3-Carbinol and Silibinin

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT03687073·21 enrolled

THISTLE - The HIV-HCV Silibinin Trial

Completed·UUniversity of Zurich·Phase 2·NCT01816490·20 enrolled

Liver Transplant2 trials

Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients

Terminated·RRottapharm·Phase 2·NCT01535092·14 enrolled

Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients

Terminated·RRottapharm·Phase 2·NCT01518933·20 enrolled

Intravenous1 trial

Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders

Completed·MMedical University of Vienna·Phase 2·NCT00684268·70 enrolled

Hepatic failure1 trial

Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning

Terminated·MMylan Specialty, LP·Phase 2·NCT00915681·148 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Silibinin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Silibinin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Silibinin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rottapharm company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRottapharm

Silibinin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Trial2 trials

Liver Transplant2 trials

Intravenous1 trial

Hepatic failure1 trial

References

Drug Info

Quick Facts

Related News